Moleculin Biotech Inc (MBRX)
3.09
+0.59
(+23.60%)
USD |
NASDAQ |
Nov 14, 16:00
2.93
-0.16
(-5.18%)
After-Hours: 17:46
Moleculin Biotech Research and Development Expense (Quarterly): 4.09M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 4.09M |
| March 31, 2024 | 4.252M |
| December 31, 2023 | 6.632M |
| September 30, 2023 | 3.28M |
| June 30, 2023 | 3.888M |
| March 31, 2023 | 5.687M |
| December 31, 2022 | 4.178M |
| September 30, 2022 | 5.965M |
| June 30, 2022 | 4.204M |
| March 31, 2022 | 4.62M |
| December 31, 2021 | 3.179M |
| September 30, 2021 | 4.095M |
| June 30, 2021 | 3.039M |
| March 31, 2021 | 4.105M |
| December 31, 2020 | 1.786M |
| September 30, 2020 | 4.435M |
| June 30, 2020 | 3.329M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.206M |
| December 31, 2019 | 3.197M |
| September 30, 2019 | 2.785M |
| June 30, 2019 | 2.099M |
| March 31, 2019 | 2.932M |
| December 31, 2018 | 2.927M |
| September 30, 2018 | 1.332M |
| June 30, 2018 | 4.231M |
| March 31, 2018 | 1.237M |
| December 31, 2017 | 2.285M |
| September 30, 2017 | 1.061M |
| June 30, 2017 | 0.515M |
| March 31, 2017 | 0.683M |
| December 31, 2016 | 0.88M |
| September 30, 2016 | 0.497M |
| June 30, 2016 | 0.105M |
| March 31, 2016 | 0.015M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.786M
Minimum
Dec 2020
6.632M
Maximum
Dec 2023
4.061M
Average
4.095M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Agilent Technologies Inc | 127.00M |
| Seelos Therapeutics Inc | 0.966M |
| Cara Therapeutics Inc | 9.308M |
| Citius Pharmaceuticals Inc | 2.764M |
| NovaBay Pharmaceuticals Inc | 0.009M |